Mesangial Cell Immune Injury
Synthesis, Origin, and Role of Eicosanoids

Elias A. Lianos,* Barbara A. Bresnahan,* and Cynthia Pan†
With the technical assistance of Beatrice Hucke and Shelley Dufek
Medical College of Wisconsin, *Departments of Medicine and †Pediatrics, Milwaukee, Wisconsin 53226

Abstract
The synthesis, cell origin, and physiologic role of eicosanoids were investigated in a model of mesangial cell immune injury induced by a monoclonal antibody against the rat thyomocyte antigen Thy-1.1 also expressed in rat mesangial cells. A single intravenous injection of the antibody resulted in enhanced glomerular synthesis of thromboxane (Tx)B₂, leukotriene (LT)B₄, and 12-hydroxyeicosatetraenoic acid (HETE), whereas that of PGF₂α and PGE₂ was either unaltered or impaired. The enhanced eicosanoid synthesis was associated with decrements in glomerular filtration rate (GFR) and renal blood flow (RBF). Complement activation mediated both the increments in TxB₂, LTB₄, and 12-HETE and the decrements in GFR and RBF. The decrements in GFR were abolished by the TXA₂ receptor antagonist SQ-29,548. Although both neutrophils and Ia (+) leukocytes infiltrated glomeruli, glomerular LTβ₁ originated mainly from the latter. Platelets entirely accounted for the enhanced 12-HETE synthesis in isolated glomeruli and to a lesser extent for that of LTβ₄ and TxB₂. Glomerular PGE₂ and PGF₂α originated from mesangial cells as their impaired synthesis coincided with extensive mesangial cell lysis. The observations indicate that in mesangial cell immune injury vasoactive and proinflammatory eicosanoids originate from recruited or activated Ia (+) leukocytes and platelets and may exert paracrine effects on mesangial cells. (J. Clin. Invest. 1991. 88:623–631.) Key words: mesangial cell • nephritis • eicosanoids • leukocytes • platelets

Introduction
The Thy-1 gene is a member of the immunoglobulin "super family" of genes and is expressed in a number of different cell types (1). The expression product is a 17-kD cell surface antigenic glycoprotein (the Thy-1 antigen) that is expressed in thyocytes, young lymphocytes, and their precursor hematopoietic stem cells, in fibroblasts and in neurons of the central nervous system (1). Rat glomerular mesangial cells have also been shown to express the Thy-1 antigen (2). In Thy-1-bearing cells this antigen is anchored to the acyl chains of membrane phosphatidylinositol and can be cleaved by a phosphatidylinositol-specific phospholipase C (3). A monoclonal antibody (ER₄, IgG2A), raised against the rat thyomocyte antigenic determinant Thy-1.1, binds to rat glomerular mesangial cells and induces a complement-dependent injury resulting in mesangial cell lysis, followed by a mesangioproliferative phase (4). This model of glomerular immune injury can, therefore, be regarded as the experimental equivalent of nephropathies involving primarily the glomerular mesangium, and provides the opportunity to investigate the biology of mesangial cell injury as it relates to synthesis of proinflammatory mediators and renal hemodynamic perturbations. We, therefore, investigated the biosynthesis, cell origin, and role of vasoactive and proinflammatory arachidonate cyclooxygenation and lipoxygenation products.

Methods
Induction of mesangial cell immune injury. Mesangial cell injury was induced by a single intravenous administration of the mouse monoclonal antibody (ER₄) raised against the rat thyomocyte antigenic determinant Thy-1.1 and generously provided by Dr. W. Bagchus, Department of Pathology, University of Groningen, The Netherlands. This antibody (molecular weight 25 kD) binds to thyocytes, bone marrow cells, peripheral blood lymphocytes, and to mesangial cells, and also demonstrates complement binding capacity (4). Male Munich-Wistar rats (165–290 g body wt) were employed and, in most experiments, two antibody doses were employed: a 2.5 and a 6 mg/kg body wt. Both doses induced proteinuria (urine protein excretion: 207±9 mg/24 h) and glomerulonephritis. The 6-mg/kg dose also induced decrements in glomerular filtration rate and renal blood flow (see below). Glomerular and mesangial cell lesions were assessed in cortical sections by routine methods of light and immunofluorescence microscopy. Light microscopy assessed changes in glomerular and mesangial cell morphology in 4–5-μm sections stained with the Hematoxylin-Eosin and Periodic acid Schiff stains as well as the presence of blood-borne leukocytes in sections stained with the Giemsa stain. Immunofluorescence microscopy (direct) was performed in 7–8-μm cortical sections and assessed deposition and distribution of the ER₄ antibody using FITC-labeled goat anti-mouse IgG and of rat complement component C₃ using FITC-labeled goat anti-rat C₃. The presence of Ia (+) cells was also assessed by direct immunofluorescence using an FITC-labeled mouse monoclonal antibody against the rat monocyte/macrophage Ia determinant (Sera-Lab, Sussex, England). The presence of Ia (+) and blood-borne leukocytes (neutrophils) was expressed as number of cells per glomerulus (mean±SEM, n = 20 glomeruli).

Biochemistry studies. These studies were performed at two early points (1 and 2 h) and at two late points (day 4 and day 14) after ER₄ antibody administration. At these time points, animals were nephrectomized and the kidneys were placed in RPMI-1640 at 4°C. Glomeruli were isolated by differential sieving, suspended in 2 ml of RPMI-1640, and incubated under constant stirring at 37°C for 30 min. At the end of this incubation period, an aliquot of the medium (100–200 μl) was sampled and assayed directly for PGE₂, PGF₂α, and TxB₂ using specific RIA for these eicosanoids as previously described (5). In the remaining glomerular suspension, the phospholipase A₂ activator A23187 was added (final concentration 2 μM) in order to assess synthesis of the
arachidonate lipoxigenation products 12-hydroxyeicosatetraenoic acid (HETE) and leukotriene (LT)B\(_4\). A second incubation in the presence of GFR\(_{1516}\) was performed at 37°C for 45 min and was terminated by the addition of 2 vol of acidified absolute ethanol. After prolonged agitation at 4°C, the ethanolic mixture of the glomerular suspensions was centrifuged in order to separate glomeruli and precipitated proteins. The supernatant was dried under vacuum, suspended in 1 ml of methanol-water-acetic acid (64:34:2 vol/vol/vol), and injected in a gradient HPLC system in order to separate and isolate HETE and leukotrienes, as previously described (6). HPLC-isolated 12-HETE and LT\(_B4\) were subsequently measured using specific RIAs as previously described (6). The glomerular pellet was solubilized in 0.1 N sodium hydroxide and used for protein determination by a colorimetric method. Results were expressed in nanograms of eicosanoid/mg glomerular protein. Sensitivities and cross-reactivities of the RIAs employed for the above eicosanoids were previously assessed and reported (6). The anti-antibody for PGE\(_2\) was purchased from the Institute Pasteur (Paris, France). The antiserum for thromboxane (Tx)B\(_2\) was a gift from Dr. W. Campbell (University of Texas Southwestern Medical School, Dallas, TX). The anti-antibody for PGF\(_{2\alpha}\) was a gift from Dr. A. Hassid (New York Medical College, Valhalla, NY). The antiserum for LT\(_B4\) was generously provided by Dr. A. Ford-Hutchinson (Merck-Frost/Canada, Dorval, Quebec, Canada). The antibody for 12-HETE was generously provided by Dr. L. Levine (Brandeis University, Wal- tham, MA).

**Physiology studies.** These studies assessed the effect of intravenous ER\(_A\) antibody administration on changes in glomerular filtration rate (GFR) and renal blood flow (RBF). Animals were anesthetized with intraperitoneal thiobutabarbital (Inactin; Byk, Gulden Konstanz, FRG), 12–15 mg/100 g body wt, and maintained at 37°C by warming on a constant temperature table. After tracheostomy, a catheter was placed in the right jugular vein for infusion of 2% albumin in 0.9% sodium chloride at a rate of 20 ml/kg/h throughout the experiment. Tritiated inulin, 0.5 \(\mu\)Ci/ml, was added to the infusion solution for measurement of GFR. The right femoral artery was cannulated for measurement of systemic blood pressure via a transducer connected to a digital pressure monitor and for collection of blood samples. Catheters were inserted into the right and left ureters for urine collection. A flow probe (1.5–2.0 mm) was placed around the left renal artery and RBF was measured using an electromagnetic flow meter (model 501; Carolina Instruments, King, NC). After completion of surgery and a 60-min stabilization period, two baseline clearance periods (15 min each) were obtained. Animals subsequently received a single intravenous injection of ER\(_A\) antibody (6 mg/kg) or mouse IgG (controls, 6 mg/kg) and urine and plasma samples were collected for determination of GFR at 1 h after administration of ER\(_A\).

In a second group of animals, GFR and RBF were assessed after decomposition in order to determine the role of complement in mediating the ER\(_A\) antibody-induced changes in these parameters. Decomplementation was achieved by the intraperitoneal injection of cobra venom factor (CVF; Cordis, Miami, FL) purified by ion exchange and gel filtration chromatography (7). 100 U per 100 g body wt was administered in four divided doses over the 24-h period preceding measurements of GFR and RBF. Animals were subsequently instrumented and GFR and RBF were measured as described above. Upon completion of these measurements rats were nephrectomized and glomeruli were isolated for assessment of eicosanoid synthesis as described above. Systemic decomposition was assessed by a modified hemolytic assay, performed in serum samples obtained from the tail vein at baseline and before initiation of the physiologic studies. To perform the assay, sensitized sheep red blood cells, \(1 \times 10^9\) cells/ml, were incubated with varying dilutions of serum samples at 37°C for 1 h and subse-

1. Abbreviations used in this paper: CVF, cobra venom factor; GFR, glomerular filtration rate; GBM, glomerular basement membrane; HETE, hydroxyeicosatetraenoic acid; LT, leukotriene; PG, prostaglandin; RBF, renal blood flow; Tx, thromboxane.

quenty centrifuged for 10 min. Absorbance (spectrophotometry) was measured at \(\lambda = 540\) nm. Decomplementation was considered complete when absorbance readings from CVF-treated animals were less than 5% baseline samples. Decomplementation was also confirmed by the absence of immunofluorescence staining for glomerular C\(_3\) deposits.

In a third group of animals, the ER\(_A\) antibody was given after pre-treatment with the TxA\(_2\) receptor antagonist SQ-29,548 \([1S-[1e,2\beta) (SZ), 38, 4a]-7-[3-[2-[(phenylamino) carbonyl] hydrazino] methyl]-7-oxacyclohex-2[2.2.1] hept-2-yl]-5-hepentoic acid; Squibb Institute for Medical Research, Princeton, NJ). This compound was given as an intravenous bolus of 2 mg/kg, followed by a constant infusion of 2 mg/kg per h for 20 min before the administration of ER\(_A\) antibody (6 mg/kg). GFR and RBF were determined before the infusion of SQ-29,548, before ER\(_A\) antibody, and at 1 h after infusion of ER\(_A\). Upon completion of these measurements, glomeruli were isolated for analysis and quantification of eicosanoids as described above.

**Leukocyte and platelet depletion studies.** Glomerular \(\lambda\) (+) leukocytes were depleted by the use of a whole animal x irradiation protocol as previously described (8). Specifically, animals were subjected to 250 KVP orthovoltage x rays with a half value of 1 mm Cu at a dose rate of 133 rad/min for a total dose of 900–1,100 rad, using parallel opposed fields. Kidneys were shielded with 6-mm thick lead blocks that covered the kidneys within 5 mm margins. Positioning of the blocks was verified with diagnostic x rays done simultaneously with treatment (port fields). Dosimetry was done in a plexiglass phantom using a Farmer-type ionization chamber. The effect of \(\mathbf{x}\) irradiation was assessed on peripheral leukocyte counts determined by an automated hematology analyzer (Coulter Electronics, Hialeah, FL) before administration of ER\(_A\) and on glomerular \(\lambda\) (+) cells, neutrophil counts, and LT\(_B4\) synthesis at 2 h after ER\(_A\). These studies employed three groups of rats that were studied at 24, 72, and 96 h after the \(\mathbf{x}\) irradiation dose.

To deplete animals of circulating platelets, a rabbit anti-rat thrombocyte immune serum was employed (Accurate Co., Westbury, NY). A single intraperitoneal injection of 1.5 ml of this serum resulted in marked and selective systemic platelet depletion within 18–24 h and was associated with prolongation in the bleeding time. After platelet depletion was confirmed in each animal by an automated hematology analyzer (Coulter Electronics), ER\(_A\) antibody (2.5 mg/kg) was injected and glomeruli were isolated 2 h later for determination of eicosanoid synthesis as described above.

**In vitro eicosanoid synthesis.** To assess whether binding of anti-Thy 1 antibody in the glomerular mesangium in vitro induces eicosanoid synthesis, glomeruli isolated from normal animals were subjected to mild enzymatic permeabilization in Hank’s balanced salt solution containing 1% Hepes, collagenase Type II, 50 U/ml (Sigma Chemical Co., St. Louis, MO), and DNAse 0.01% (Sigma Chemical Co.). After washing off the permeabilization solution, glomeruli were incubated with ER\(_A\) antibody (2 mg/ml; \(n = 4\) or mouse IgG (2 mg/ml; \(n = 4\) in the presence of 10% rat serum or plasma as a source of complement. Incubations were performed at 37°C for 45 min in a manner similar to that employed in glomeruli isolated from animals that had received ER\(_A\) injections. Binding of ER\(_A\) antibody and of rat complement C\(_3\) to the glomerular mesangium was documented by immunofluorescence microscopy in an aliquot of glomeruli at the end of the incubations. Glomerular incubations were terminated by the addition of 2 vol of absolute ethanol, and extracts were processed for isolation and quantification of LT\(_B4\) and 12-HETE using HPLC and RIA as described above.

**EXPERIMENTAL GROUPS.**

1. **Time course studies.** Animals receiving 2.5 mg/kg of antibody ER\(_A\) and killed at 1 h (\(n = 6\)), 2 h (\(n = 10\)), 4 d (\(n = 4\)), and 14 d (\(n = 4\)) after antibody administration. Parallel controls receiving mouse IgG and studied at 1 h (\(n = 5\)), 2 h (\(n = 10\)), 4 d (\(n = 8\)), and 14 d (\(n = 4\)).

2. **Physiology studies.** (a) Animals receiving ER\(_A\) antibody 6 mg/kg (\(n = 8\)) or nonimmune mouse IgG (controls, \(n = 6\)) and studied at 1 h. (b) Decomplemented animals receiving ER\(_A\) antibody 6 mg/kg (\(n = 8\)) and decomplemented controls receiving nonimmune mouse IgG (\(n = 8\)) and nonimmune mouse IgG (controls, \(n = 6\)) and studied at 1 h.
3. Studies in x irradiated animals: These were performed at 24 h (n = 6), at 72 h (n = 6), or at 96 h (n = 6) after x irradiation. At these time points animals received ER4 antibody (2.5 mg/kg) and glomerular eicosanoid synthesis was assessed 2 h later.

4. Platelet depletion studies. Animals received a single injection of anti-thrombocyte serum 18–24 h before ER4 antibody (2.5 mg/kg; n = 6). Glomerular eicosanoid synthesis was assessed at 2 h after injection of ER4.

Statistical analyses employed the two-way analysis of variance for repeated measurements followed by a Duncan multiple range test and the Student’s t test for unpaired observations, as dictated by the experimental designs. Results were expressed as mean±SEM.

Results

Effects of ER4 on glomerular histopathology. Fig. 1 demonstrates glomerular deposition of the monoclonal antibody ER4 at 1 h (Fig. 1 A) and 14 d (Fig. 1 B) after a single intravenous injection. The antibody initially localized in the glomerular mesangium (Fig. 1 A). It subsequently redistributed towards peripheral glomerular capillary loops (Fig. 1 B). Fig. 2 demonstrates the presence of glomerular Ia (+) cells in a control glomerulus (Fig. 1 A), at 2 h (Fig. 2 B), and on day 14 (Fig. 2 C) after a single intravenous injection of the ER4 antibody. There was an increase in Ia (+) cells throughout the glomerulus at 2 h and a sustained increment in these cells on day 14, at which point their location was peripheral. Fig. 3 demonstrates the changes in glomerular cellularity at various time points after ER4 antibody administration. Increased cellularity was noted at 1 to 2 h (Fig. 3 B) compared with control (Fig. 3 A). On day 4 (Fig. 3 C), glomerular hypocellularity with marked absence of mesangial cells was apparent. On day 14 (Fig. 3 D), glomerular cellularity recovered and there was also an increase in mesangial matrix.

Effects of ER4 on glomerular eicosanoid synthesis: correlation with leukocyte infiltration. In Fig. 4 the changes in glomerular synthesis of TxB2, PGE2, and PGF2α compared with pooled synchronous controls are shown at the various time points after a single intravenous administration of ER4 antibody (2.5 mg/kg). There was a progressive and sustained increment in TxB2 that spanned all time points of study. In contrast, the synthesis of PGE2 and PGF2α progressively declined and reached a nadir on day 4. The synthesis of these two eicosanoids subsequently recovered (day 14) to control levels.

In Fig. 5 the glomerular synthetic profiles of LTB4 and 12-HETE, at the various time points after a single intravenous injection of ER4 (2.5 mg/kg), are shown in parallel with LTB4 and 12-HETE values obtained in synchronous controls. The synthesis of 12-HETE in animals receiving ER4 was significantly enhanced at 2 h after antibody administration and remained increased at statistically significant levels at all subsequent time points compared with synchronous controls. In contrast to 12-HETE, significant increments in glomerular LTB4 synthesis occurred earlier (1 h) but spanned a shorter period of time and returned toward control levels on day 4. LTB4 synthesis remained significantly higher than synchronous controls on day 4 (0.51±0.10 vs. 0.24±0.04; P < 0.05) and was no different than controls on day 14. Fig. 6 demonstrates changes in glomerular Ia (+) and neutrophil cell counts.

Counts of both cell types were significantly higher at all time points compared with synchronous controls. Whereas the increments in glomerular 12-HETE and LTB4 were temporarily associated with the increments in glomerular Ia (+) and neutrophil cell counts at 1 and 2 h after administration of ER4 (Figs. 5 and 6), at later time points (days 4 and 14), LTB4 values returned toward control levels (Fig. 5) despite a sustained increase in glomerular Ia (+) cell and neutrophil counts (Fig. 6). 12-HETE synthesis remained significantly increased at all time points.
Effects of x irradiation and platelet depletion on glomerular eicosanoid synthesis. Table 1 demonstrates the correlation between glomerular LTB4 synthesis and glomerular neutrophil and Ia (+) cell counts determined 2 h post-ER4 and peripheral leukocyte counts assessed before ER4 administration in the three groups of animals studied at 24, 72, and 96 h after x irradiation dose. Peripheral leukopenia and a relative reduction in glomerular neutrophils after x irradiation were present in all groups. Post-ER4 glomerular LTB4 synthesis was significantly reduced only in glomerular preparations isolated from animals studied 96 h after x irradiation. In this group glomerular Ia (+) cell counts were also abolished. In the groups studied 24 and 72 h post-x irradiation, although marked peripheral leukopenia and glomerular reduction of neutrophils were present, glomerular LTB4 synthesis measured 2 h post-ER4 was not different compared with levels obtained in glomeruli isolated from nonirradiated rats studied 2 h after ER4 antibody administration (Table I).

Figure 2. Immunofluorescence localization of glomerular Ia (+) cells in a control glomerulus (A), at 2 h (B), and on day 14 (C) after ER4 administration.

Figure 3. Light microscopy demonstrating changes in glomerular cellularity after a single administration of ER4 antibody. (A) Control glomerulus; (B) 2 h post-ER4; (C) day 4, post-ER4; (D) day 14, post-ER4.
these three eicosanoids most notable on day 4. *P < 0.05, TxB2 compared with pooled controls.

The effect of platelet depletion and of x irradiation on glomerular TxB2, 12-HETE, and LTB4 synthesis assessed at 2 h after administration of ER4 (2.5 mg/kg) is shown in Fig. 7. The ER4-induced increments in glomerular 12-HETE synthesis were abolished in the platelet-depleted group compared with the group that received ER4 antibody alone (Fig. 7). In this group, glomerular TxB2 and LTB4 synthesis were also significantly reduced; however, they remained significantly higher compared with control values. In the x irradiated group (96 h postirradiation), glomerular TxB2 and 12-HETE synthesis were not significantly different compared with the group that received ER4 antibody alone. In contrast, LTB4 synthesis was significantly reduced.

The antiplatelet antibody employed markedly reduced circulating platelet counts (from 929±37 to 8.3±2.1×10^5/μl; n = 6) and had an insignificant effect on circulating leukocyte counts (from 10.9±0.8×10^3 to 8.6±1.3×10^3/μl; n = 6) assessed at 18 h after a single intraperitoneal injection of the antibody. X irradiation had no effect on circulating platelet counts assessed at 96 h (940±15×10^3/μl) or on serum complement assessed by hemolytic assay at the same time point (hemolysis of sensitized sheep RBCs measured spectrophotometrically as hemoglobin absorbance units: base line = 0.700±0.005 vs. post-x irradiation, 0.727±0.024).

In vitro effect of ER4 antibody on glomerular eicosanoid synthesis. Fig. 8 demonstrates binding of ER4 antibody (Fig. 8 A) and of rat C3 (Fig. 8 B) in isolated enzymatically permeabilized glomeruli incubated with the monoclonal antibody ER4 (2 mg/ml) in the presence of 10% rat serum (source of complement). Fig. 8 C is a control glomerulus incubated with mouse IgG and stained for rat C3. There was no change in glomerular LTB4 synthesis in permeabilized glomeruli incubated with ER4 antibody compared with control glomeruli incubated with mouse IgG (LTB4; 0.9±0.2 ng/mg glomerular protein in glomeruli incubated with ER4 and 1.7±0.2 ng/mg glomerular protein in glomeruli incubated with mouse IgG). Because the rat serum used as a source of complement was found to contain high levels of 12-HETE (866 ng/ml of serum containing medium), two additional experiments using rat plasma as a complement source were performed in order to assess changes in glomerular 12-HETE synthesis in response to ER4 binding. The levels of 12-HETE in rat plasma containing media were 47 ng/ml. In permeabilized glomeruli incubated with ER4 (2 ng/ml) in the presence of 10% rat plasma 12-HETE synthesis was 206 ng/mg glomerular protein. In control glomeruli incubated with mouse IgG 12-HETE synthesis was 260 ng/mg protein.

Effects of ER4 on GFR and RBF: role of complement and of Tx receptor antagonism. Fig. 9 demonstrates the effect of complement depletion and of thromboxane receptor antagonism with SQ-29,548 on ER4 antibody-induced decrements in GFR and RBF. The glomerular eicosanoid synthetic profiles corresponding to the four groups of animals studied and determined upon completion of the GFR and RBF measurements are shown in Table II. In both the complement-depleted group and the SQ-29,548-treated group the decrements in GFR and RBF were ameliorated to levels not different from each other and significantly higher than the group receiving ER4 alone. In the SQ-29,548-pretreated rats, GFR and RBF values were no different compared with the decomplemented group of rats receiving mouse IgG (controls). In the decomplemented group receiving ER4, the glomerular synthesis of TxB2, LTB4, and 12-HETE were significantly lower compared with the complement replete group receiving ER4 (Table II). In the SQ-29,548-pretreated group the synthesis of these eicosanoids was no different than the group receiving ER4 alone.

Discussion

Enhanced eicosanoid synthesis in isolated glomeruli has been demonstrated in various forms of experimental and clinical glomerulopathies. Studies have focused on identifying the type of eicosanoid(s) synthesized after initiation of immune injury and their role in mediating vasoactive and proinflammatory events occurring in the progression of injury. Increased synthesis of both arachidonate cyclooxygenation and lipoxigenation metabolites has been demonstrated (9). Of the former, increased glomerular synthesis of thromboxane has been consistently shown in most forms of antibody-mediated renal injury and has been implicated in effecting adverse hemodynamic effects such as decrements in GFR and RBF (9). Of the arachi-
donate lipoxigenation metabolites, HETE and leukotrienes have been best characterized (6, 10). Both vasoactive and proinflammatory roles have been attributed to these metabolites. Thus, antagonism of the LTD4 receptor prevents anti-glomerular basement membrane (GBM) antibody-mediated acute decrements in GFR (11), and essential fatty acid-deficient diets inhibit glomerular LTBA synthesis and ameliorate the hemodynamic and histopathological severity of anti-GBM glomerular injury (12).

The cell of origin of "glomerular" eicosanoids has been an issue of debate. In antibody-mediated models of glomerular immune injury, it seemed reasonable to assume that the injured glomerular cell was a likely source of eicosanoids. This was a particularly reasonable assumption in models employing antibodies directed against antigens of specific glomerular cells (i.e., antibodies against the Fx1A antigen of glomerular epithelial cells) that, when cultured, were capable of eicosanoid synthesis. This assumption was strengthened further when the role of hematogenous cells capable of eicosanoid synthesis was assessed in infiltrative models of glomerular immune injury. Thus, in anti-GBM disease, an infiltrative form of experimental glomerulonephritis, it was demonstrated that platelets did not contribute to the enhanced glomerular 12-HETE synthesis (13) and, in the same disease model, neutrophil depletion only partially contributed to the enhanced glomerular LTBA synthesis (6).

Likewise, in a different model of infiltrative glomerulonephritis, induced by administration of cationized gamma globulin, enhanced glomerular LTBA synthesis persisted in neutropenic rats (10). Several lines of evidence, however, indicate that cells other than those on which immunologic reactants (i.e., antibody and complement components) bind may account for the enhanced eicosanoid synthesis observed in glomeruli isolated after initiation of injury. (a) Isolated normal glomeruli synthesize measurable amounts of LTBA and 12-HETE when incubated with the phospholipase A2 activator, A23187 (6), yet, none of the glomerular cell populations in culture (epithelial, mesangial, endothelial) express the arachidonate 5-lipooxygenase gene (14, 15). (b) In glomerular epithelial cell injury mediated by anti-Fx1A antibody, there is enhanced glomerular LTBA synthesis despite the fact that glomerular epithelial cells in culture do not synthesize LTBA and glomeruli do not show infiltration by leukotriene-producing cells (i.e., leukocytes) after anti-Fx1A administration (16). (c) Diets deficient in essential fatty acids, or bone marrow depletion using whole animal x irradiation, abolish glomerular LTBA synthesis, and this event was convincingly correlated with depletion of glomerular La-bearing monocytes (17), an observation that points to this cell type as a likely source of arachidonate lipoxigenation products in glomeruli.

On the basis of these controversial observations, we reasoned that because the eicosanoid synthetic profile of mesangial cells is well characterized (18) and the role of mesangial cells in regulating glomerular filtration emphasized (19), the model of anti-Thy 1 antibody-induced mesangial cell injury is most suitable to study origin and physiologic role of eicosanoids. The demonstration that the Thy-1 antigen is specifically linked to membrane phosphatidylinositol in Thy-1-bearing cells (3), lends further suitability to this model of immune injury for study of the origin and role of eicosanoids.

Our observations indicate that in mesangial cell immune injury induced by the monoclonal anti-Thy 1 antibody ERa, cells other than the injured mesangial account for the enhanced glomerular eicosanoid synthesis. Moreover, different cells account for the synthesis of different eicosanoids. This is best illustrated in Fig. 4, where the dichotomy in the synthesis of the three arachidonate cyclooxygenation products, PGE2, PGF2a, and TXB2, is shown. This dichotomy is most apparent on day 4, when TXB2 synthesis was at a maximum, while that of PGE2 and PGF2a was at a minimum and at levels lower than controls. As the nadir in PGE2 and PGE2a synthesis (Fig. 4) correlated with glomerular hypocellularity and mesangial cell depletion (Fig. 3C), we propose that the origin of these two eicosanoids is the mesangial cell. This contention is supported by the well established profile of eicosanoids in cultured mesangial cells that includes primarily PGE2 and PGF2a (18). The recovery in PGE2 and PGF2a synthesis on day 14 after administration of ERa (Fig. 4) could be due to a mesangioproliferative phase (Fig. 3D), which follows the mesangiolytic phase as previously described in this model (4, 20).

That the La (+) leukocyte is a likely source of glomerular LTBA is supported by the following two observations: (a) In x

Table I. Effect of X-Irradiation on Peripheral Leukocyte Counts (WBC) before ERa Administration and on Glomerular La (+) Cell and Neutrophil Counts and Glomerular LTBA Levels, 2 h after ERa Administration

<table>
<thead>
<tr>
<th></th>
<th>WBC × 10³/µl</th>
<th>La (+) cells/glomerular</th>
<th>PMN/glomerular</th>
<th>LTBA mg/mg protein</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-ERa</td>
<td>2 h Post-ERa</td>
<td>2 h Post-ERa</td>
<td>2 h Post-ERa</td>
</tr>
<tr>
<td>No irradiation (n = 10)</td>
<td>10.4±0.4</td>
<td>7.3±2.1</td>
<td>5.0±0.7</td>
<td>13.7±2.7</td>
</tr>
<tr>
<td>24 h post-irradiation (n = 8)</td>
<td>2.20±0.7*</td>
<td>4.8±2.2</td>
<td>1.6±0.5*</td>
<td>12.9±0.1</td>
</tr>
<tr>
<td>72 h post-irradiation (n = 6)</td>
<td>1.90±0.4*</td>
<td>2.5±1.4*</td>
<td>1.4±0.4*</td>
<td>12.3±1.7</td>
</tr>
<tr>
<td>96 h post-irradiation (n = 6)</td>
<td>1.97±0.3*</td>
<td>0.8±0.6*</td>
<td>2.1±0.3*</td>
<td>4.6±0.3*</td>
</tr>
</tbody>
</table>

PMN, polymorphonuclear leukocyte. *P < 0.05 compared with no irradiation.

---

**Figure 7.** Effect of platelet depletion and of x irradiation (96 h protocol) on glomerular TXB2, LTBA, and 12-HETE synthesis assessed at 2 h after ERa antibody administration. X irradiation significantly reduced LTBA synthesis only. Platelet depletion significantly reduced TXB2 and LTBA synthesis and abolished 12-HETE synthesis. Control (c); ERa (a); X irradiated (b); platelet depleted (m). *P < 0.05 compared with controls. **P < 0.05 compared with ERa.
irradiated animals, enhanced glomerular LTB$_4$ synthesis determined 2 h post-ER$_4$ continued in a manner independent of peripheral leukocyte counts and of glomerular neutrophil counts (Table I). It was abolished only in animals studied 96 h after x irradiation, when glomerular Ia (+) cell counts were also abolished (Table I); (b) binding of ER$_4$ in permeabilized glomeruli (Fig. 8) originating from normal animals and in the presence of rat serum did not result in enhanced LTB$_4$ or 12-HETE synthesis. Cell types possessing the Ia antigen that could account for the enhanced glomerular LTB$_4$ synthesis include: elicited monocyte-macrophages, activated lymphocytes, activated glomerular endothelial cells, and the mesangial cell itself (21). As there is no evidence that lymphocytes synthesize 5-HETE or LTB$_4$ (22), or that glomerular epithelial, endothelial, or mesangial cells express the 5-lipoxygenase gene (14), we propose that the Ia (+) monocyte-macrophage is the likely source of LTB$_4$. Our observations do not entirely rule out the neutrophil as a potential source of LTB$_4$. As shown in Figs. 5 and 6, the increments in glomerular LTB$_4$ at 1 and 2 h coincided with increments in both glomerular Ia (+) and neutrophil counts. However, on days 4 and 14 after ER$_4$, LTB$_4$ synthesis returned toward control levels despite significant glomerular infiltration by neutrophils (Fig. 6). Moreover, in x irradiated leukopenic animals, glomerular depletion of neutrophils did not result in decreased glomerular LTB$_4$ synthesis after ER$_4$ (Table I). These observations indicate that the infiltrating neutrophil does not entirely account for the enhanced glomerular LTB$_4$ synthesis after administration of ER$_4$. The reason for the discrepancy between glomerular Ia (+) and neutrophil cell counts and LTB$_4$ levels on days 4 and 14 (Figs. 5 and 6) is not clear. Specifically, it is not clear why LTB$_4$ synthesis returned toward control levels despite the sustained increase in glomerular Ia (+) and neutrophil counts. A similar phenomenon was previously described in anti-GBM antibody-induced injury, an infiltrative type of glomerular immune injury, in which the enhancement in glomerular LTB$_4$ synthesis was again short lived and did not correlate with glomerular neutrophil infiltration (6).

The enhanced glomerular LTB$_4$ synthesis was complement dependent (Table II) and this might be accounted for by the effect of complement activation and anaphylatoxin release on glomerular leukocyte infiltration. In addition, it is possible that binding of anaphylatoxin (C5a), generated after intraglomerular complement activation, on Ia-bearing macrophages results in enhanced LTB$_4$ synthesis either directly or via a mechanism involving IL-1. Specific receptors for C5a have been demonstrated on murine Ia-bearing macrophages and binding of C5a on these receptors induces IL-1 secretion (23). IL-1, in turn, is a known eicosanoid synthesis agonist.

**Table II. Glomerular Eicosanoid Synthesis (ng/mg Glomerular Protein) 1 h after ER$_4$ or Mouse IgG Administration in Normal, Decomplemented (CVF + ER$_4$), and TxA$_2$ Receptor Antagonist (SQ-29,548 + ER$_4$)-pretreated Rats**

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>ER$_4$</th>
<th>CVF + ER$_4$</th>
<th>SQ-29,548 + ER$_4$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 6</td>
<td>n = 8</td>
<td>n = 8</td>
<td>n = 6</td>
</tr>
<tr>
<td>TxB$_2$</td>
<td>4.9±0.6*</td>
<td>11.4±1.0*</td>
<td>7.4±1.1*</td>
<td>14.4±2.0</td>
</tr>
<tr>
<td>LTB$_4$</td>
<td>0.7±0.1*</td>
<td>11.4±2.6</td>
<td>4.9±0.8*</td>
<td>11.4±3.0</td>
</tr>
<tr>
<td>12-HETE</td>
<td>46±12*</td>
<td>988±75*</td>
<td>263±57*</td>
<td>1532±308</td>
</tr>
</tbody>
</table>

* P < 0.05 compared with ER$_4$.  

Eicosanoids and Mesangial Nephritis 629

---

**Figure 8.** Binding of the ER$_4$ antibody (A) and rat C$_3$ (B) in isolated enzymatically permeabilized normal glomeruli. C is a control glomerulus stained for C$_3$. 

**Figure 9.** Effects of complement depletion and of pretreatment with the TxA$_2$ receptor antagonist SQ-29,548 on the decrements in GFR and RBF induced by administration of ER$_4$. In the group pretreated with SQ-29,548, GFR and RBF were ameliorated to levels no different than those of the decomplemented group. There were no differences in GFR and RBF between complement replete (n = 6) and decomplemented rats (n = 6) that received mouse IgG. Decomplemented controls (-o-), controls, ER$_4$ (+,), decomplemented + ER$_4$ (-o-), and SQ-29,548 + ER$_4$ (-a-).
The dependence of glomerular LTB₄ synthesis on platelets is intriguing (Fig. 7), mainly because platelets do not synthesize LTB₄. Thus, this observation raises the possibility for a platelet–leukocyte interaction resulting in LTB₄ synthesis. The platelet could generate an eicosanoid synthesis agonist (i.e., PDGF or TGF-β). It may provide arachidonate, which can subsequently undergo 5-lipoxygenation to LTB₄ by 5-lipoxygenase-containing leukocytes (24), or it may augment LTB₄ production by leukocytes through a mechanism involving generation of 12-HPETE (25). In the latter case, however, one would expect the enhanced glomerular 12-HETE synthesis to precede that of LTB₄, an event that was not noted in our time course studies (Fig. 5), which demonstrate that the enhanced LTB₄ synthesis preceded that of 12-HETE. The complement system may also play a role in mediating platelet recruitment and/or activation, thereby promoting platelet-leukocyte interactions. In mesangial cell injury induced by a polyclonal rabbit anti-rat thymocyte antibody, it was demonstrated that complement depletion using CVF reduced glomerular platelet infiltration (26). As can be concluded from Fig. 7, platelets accounted for the glomerular 12-HETE and TxB₂ synthesis. Of these two eicosanoids, the effect on 12-HETE was the most striking. In contrast, TxB₂ levels remained elevated compared with controls. In contrast to platelet depletion, x irradiation, followed by a 96-h waiting period, had no effect on glomerular TxB₂ or 12-HETE synthesis (Fig. 7). As this x irradiation protocol depletes glomeruli of la-bearing monocytes (reference 8 and Table 1), our observations indicate that this cell population does not entirely account for the sustained increments in glomerular TxB₂ or 12-HETE synthesis after administration of ER4. This contrasts with the observations of Stahl and co-workers, who reported a monocyte dependence of glomerular TxB₂ synthesis in a model of mesangial cell injury using rabbit polyclonal antibody against the rat thymocyte (27). This discrepancy could be due to the different experimental approaches employed in order to deplete monocytes, namely, immune monocyte depletion (27) versus x irradiation, which causes bone marrow depletion and progressive glomerular la (+) cell depletion.

Our data indicate that the protective effect of complement depletion on GFR and RBF was associated with decreased glomerular synthesis of TxB₂, LTB₄, and 12-HETE (Table II). The protective effect of complement depletion can be accounted for by the decrements in thromboxane synthesis, as pretreatment with the TxAr receptor antagonist SQ-29,548 ameliorated the ER4-induced decrements in GFR to an extent similar to that noted in complement-depleted animals (Fig. 9) and had no effect on TxB₂, LTB₄, or 12-HETE synthesis (Table II). That thromboxane mediates the acute decrements in GFR is also supported by the recent observations of Stahl and co-workers, who demonstrated that thromboxane synthase inhibition ameliorated the anti-thymocyte antibody-induced decrements in GFR (27). Whether the enhanced synthesis of LTB₄ or 12-HETE have a vasoactive effect and contribute to the decrements in GFR is speculative. A synergistic effect to thromboxane is likely because 12-HETE has recently been shown to vasocostrict the rat vasculature (28) and essential fatty acid-deficient diets inhibit glomerular LTB₄ and ameliorate decrements in GFR and RBF in glomerular immune injury induced by anti-GBM antibody (12). The availability of specific 12-lipoxygenase or 5-lipoxygenase inhibitors should allow definitive conclusions to be made on the role of 12-HETE and LTB₄ in mediating the decrements in GFR and RBF. Moreover, study of the effect of platelet depletion on renal hemodynamic perturbations occurring in mesangial cell immune injury would allow unravelling of the role of platelet-derived vasoactive eicosanoids, such as TX and 12-HETE.

In summary, we have demonstrated that the enhanced synthesis of eicosanoids in glomeruli isolated from rats with mesangial cell immune injury originates from cells other than the mesangial cell. The la (+) leukocyte is a likely source of LTB₄ by a mechanism involving interactions with the complement system and the platelet. The stimulus for LTB₄ synthesis, however, is short lived and the participation of the neutrophil cannot be entirely ruled out. The platelet entirely accounts for the enhanced 12-HETE and partially accounts for the enhanced thromboxane synthesis. Complement activation mediates the acute decrements in GFR and RBF after mesangial cell injury via a mechanism involving enhanced eicosanoid synthesis and specifically thromboxane.

Our observations are of significance in that they implicate the platelet and the leukocyte as sources of proinflammatory and vasoactive eicosanoids in mesangial cell immune injury. Both cell types are capable of synthesizing and releasing potent noneicosanoid proinflammatory factors that can mediate proliferation (i.e., PDGF), matrix synthesis (i.e., TGF-β), cytotoxicity (i.e., TNF), and immunoregulation (interleukins). The timed or sustained synthesis of specific eicosanoids by these cells may, therefore, play an important role in regulating the synthesis or release of these proinflammatory factors in an autocrine or paracrine manner.

Acknowledgments

Cindy Ziebell provided expert secretarial assistance.

This work was supported by a United States Public Health Service Grant, RO1-DK-34793, and an American Heart Established Investigatorship to Dr. Lianos, and a United States Public Health Service National Research Service Award F32-DK-08243 to Dr. Bresnahan.

References


